News
CNSY
3.520
-9.04%
-0.350
Weekly Report: what happened at PSTV last week (0727-0731)?
Weekly Report · 22h ago
Plus Therapeutics to trade on Nasdaq as Cerenome under CNSY ticker from Aug. 3
PUBT · 3d ago
Press Release: Cerenome Launches as an Integrated CNS Oncology Company
Dow Jones · 3d ago
Cerenome Launches as an Integrated CNS Oncology Company
Barchart · 4d ago
Weekly Report: what happened at PSTV last week (0720-0724)?
Weekly Report · 07/27 09:01
Plus Therapeutics’ CNSide Diagnostics Signs Regional Agreement With Medical Mutual Covering ~1.2M People Throughout Ohio And Kentucky, To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Assay
Benzinga · 07/21 11:35
Plus Therapeutics signs Medical Mutual coverage deal for CNSide CSF tumor cell assay in Ohio, Kentucky
PUBT · 07/21 11:30
PLUS THERAPEUTICS - TO CHANGE NAME TO CERENOME, AND TICKER TO CNSY ON AUGUST 3, 2026
Reuters · 07/21 11:30
Weekly Report: what happened at PSTV last week (0713-0717)?
Weekly Report · 07/20 09:01
Plus Therapeutics Partners With Genomic Testing Cooperative To Integrate GTC's Next-Generation Sequencing Technology Into The CNSide Cerebrospinal Fluid Assay Platform
Benzinga · 07/16 11:37
Plus Therapeutics, Genomic Testing Cooperative partner on sequencing technology
TipRanks · 07/16 11:35
PLUS THERAPEUTICS AND GENOMIC TESTING COOPERATIVE PARTNER TO INTEGRATE NEXT-GENERATION SEQUENCING INTO THE CNSIDE® CSF ASSAY PLATFORM
Reuters · 07/16 11:31
Plus Therapeutics partners with Genomic Testing Cooperative to add NGS to CNSide CSF assay platform
PUBT · 07/16 11:31
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
Barchart · 07/16 06:30
Plus Therapeutics reports NCCN Central Nervous System Cancers guidelines update
TipRanks · 07/14 11:40
Plus Therapeutics Highlights Updated NCCN CNS Cancer Guidelines Reinforcing CSF Analysis In Leptomeningeal Metastases Care
Benzinga · 07/14 11:34
Plus Therapeutics flags availability of CNS cancers guidelines update release
PUBT · 07/14 11:31
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Barchart · 07/14 06:30
Weekly Report: what happened at PSTV last week (0706-0710)?
Weekly Report · 07/13 09:01
Weekly Report: what happened at PSTV last week (0629-0703)?
Weekly Report · 07/06 09:01
More
Webull provides a variety of real-time CNSY stock news. You can receive the latest news about Cerenome, Inc through multiple platforms. This information may help you make smarter investment decisions.
About CNSY
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.